Aoyi Tech Secures Nearly RMB 100 Million in Pre-B Financing Led by Wisdom Interconnect Industry Fund and Zhongyuan Qianhai Fund, with ECF Capital as Exclusive Financial Advisor

VCBeat learned第一时间 that recently, OYMotion Technology Co., Ltd. (referred to as OYMotion) has completed a nearly 100-million-yuan Pre-B round of financing. This round of financing was led byQianhai Ark's Smart Interconnection Industry Fund and Central Plains Qianhai Fund led the investment., Xingtuo Capital, Zhang Yang, chairman of Sanbo Brain, a well-known industrial investor in brain science, and the founder of Shanghai Deji Hospital/Qingdao University Shanghai Brain Medical Center followed up with investment,CEC Capital served as the exclusive financial advisor to OYMotion in this transaction.。

The funds from this round of financing will help OYMotion quickly build a brain science and neural interface technology platform, expand the R&D and manufacturing capabilities of robots, accelerate the research and clinical development of the neurorehabilitation exoskeleton product pipeline, and further promote the commercialization of the world's leading intelligent bionic hand.

OYMotion is a leading domestic company in the frontier technology of brain-machine and electromyography neural interfaces. By integrating underlying technologies such as brain-computer interface, electromyography neural interface, artificial intelligence, and exoskeleton robot-human interaction, it applies these innovations to a diverse product portfolio including neurorehabilitation exoskeleton robots, intelligent bionic hands, and electroencephalogram machines, establishing itself as a platform-based technology company in the field of neuroscience.

OB-1000 Wireless EEG Machine

OYMotion boasts a core team of medical-engineering crossover experts from top universities and medical institutions both in China and abroad. Equipped with core patents and technological barriers in brain-computer interfaces, electromyography (EMG) neural interfaces, and AI algorithms, the team has spent years independently developing China’s first three-level product matrix of upper-limb exoskeleton rehabilitation robots based on the neuroplasticity medical theory. This innovation achieves precise and personalized rehabilitation treatment, comprehensively covering both in-hospital and at-home rehabilitation scenarios. Currently, whether performed by rehabilitation therapists or assisted by existing rehabilitation medical devices, clinical outcomes remain highly limited, with approximately 80% of stroke patients still experiencing significant upper-limb motor dysfunction after hospital-based rehabilitation. OYMotion's in-hospital exoskeleton products facilitate active rehabilitation through brain-computer interface-driven neural circuit remodeling, significantly enhancing clinical rehabilitation effectiveness. Meanwhile, its at-home exoskeleton products not only allow patients to bring rehabilitation into their homes but also serve as intelligent assistive devices that complement patients' limb functionality. These solutions represent the ultimate answer for tens of millions of patients with central nervous system injuries, such as stroke, traumatic brain injury, and cerebral palsy, enabling their social reintegration and meaningful recovery.

OHand Bionic Hand

In addition to rehabilitation medicine, the company has completed a full-scale mature layout of products such as intelligent bionic hands, medical electroencephalographs (EEG), and electromyography (EMG) wristbands. It has accumulated a technological moat and engineering implementation capabilities in related fields, achieving complete independent research and development of core components with extremely strong technical reusability and product conversion ability. The company’s intelligent bionic hand product, OHand, is currently the bionic hand with the most gestures globally and the most accurate AI intent recognition, leading globally in terms of technology and performance. It truly achieves human-machine interaction, making machinery an extension of the body and consciousness. Currently, OHand is the only intelligent bionic hand included in the China Disabled Persons' Federation (CDPF) recommended assistive devices catalog and local CDPF procurement lists. It has partnerships with more than 150 top domestic and international prosthetic rehabilitation centers and has expanded to overseas markets in Northeast Asia, Southeast Asia, and Europe.

OYMotion Founder Hua Liang Ni stated"Thanks to the recognition from investors in this round and the professional services of Easy Capital, OYMotion is committed to becoming a globally leading technology company in brain science and neurology. After this round of financing, the company will accelerate the R&D and clinical progress of its Brain-Computer Interface (BCI) neurorehabilitation exoskeleton robot product matrix, providing better in-hospital and at-home solutions for patients with central nervous system injuries."

Li Peng, Managing Director of Qianhai Ark, stated"OYMotion has developed the world's leading bionic hand in terms of product performance and AI intention recognition algorithms, providing high-performance and cost-effective intelligent assistive devices for people with limb disabilities in China. Currently, the company is extending the same technology platform to create China's first brain-computer interface neurorehabilitation upper limb exoskeleton robot, expanding its market to tens of millions of neurorehabilitation patients. We are highly confident in the company’s product technology and market prospects."

Liu Zehui, partner of Xingtuo Capital, stated"OYMotion has validated the team's robust software and hardware algorithm capabilities as well as product engineering implementation through its intelligent bionic hand product. The upcoming product portfolio of upper limb exoskeleton robots for in-hospital and out-of-hospital neurological rehabilitation will not only enhance clinical rehabilitation outcomes via in-hospital brain-computer interface (BCI) exoskeletons but also provide home-based solutions for patients unable to achieve clinically significant rehabilitation. Wearing exoskeletons, these patients can reintegrate into social life and work, transforming the endgame of rehabilitation and filling a significant market gap. OYMotion’s focus on rehabilitation and bionic science aligns with Star Capital's 'Healthy Living' investment philosophy. Moreover, the resources and network within our health industry will support the company’s rapid and healthy growth."

Zhang Yang, Chairman of Sanbo Brain, said"Since the launch of China's Brain Project in 2016, brain science research has been elevated to the national scientific development strategy level. OYMotion is a leading enterprise in the field of non-invasive brain-computer interface product technology in China. Its core product under development focuses on the application of non-invasive brain-computer interfaces in neurorehabilitation. Not only does this product have significant market potential and high technical barriers, but it also demonstrates remarkable clinical rehabilitation effects for patients with central nervous system injuries, making it a rare and valuable technology and product in China’s neurorehabilitation field."

Professor Guo Hui, founder of Shanghai Deji Hospital/Qingdao University Shanghai Neuroscience Medical Center, stated"Brain-computer interface is a key focus for the future industrial cluster development in Shanghai, and Deji Hospital is also at the forefront of domestic medical institutions in the field of advanced brain science research and technology transformation. We are delighted to see the outstanding team and product technology of OYMotion in related fields, and we will further deepen our cooperation with OYMotion in scientific research, clinical applications, and product development in the future."

Wang Bin, Managing Director of Easy Capital, said"We are delighted to have assisted OYMotion in successfully completing this round of financing, further advancing product development and clinical applications. We also believe that the OYMotion team can continue to build a leading brain science and neurorehabilitation technology platform in China and even globally, creating outstanding products with clinical, commercial, and social value."

The Smart Interconnection Industry Fund, a hundred-billion-scale fund jointly initiated by Qianhai Ark Asset Management Co., Ltd.—the management institution of China's largest market-oriented commercial mother fund—China Telecom Group, and China Internet Investment Fund Management Co., Ltd., is committed to building a professional top-tier fund for the smart interconnection industry. The fund focuses on the pan-5G track and primarily invests in areas such as new healthcare, new connectivity, new energy, new materials, new computing, and new security.

Starry Capital was founded in 2018, with the founding team coming from top-tier VC institutions and leading industry companies in China. The core members possess broad international perspectives, extensive investment experience, and deep industry resources. With the mission of "Investing to Change Lives," Starry Capital focuses on investments in the fields of life health, technology innovation, and new lifestyles over the long term. The Starry team has an outstanding investment track record, having invested in numerous unicorns and industry-leading enterprises. The main investors in the managed funds include well-known market-oriented mother funds, listed companies, and government-guided funds.

CEC Capital is a leader in China's new economy investment banking, focusing on three major industries globally: TMT, consumer, and healthcare. In addition to its investment banking services, CEC Capital manages both a Renminbi fund and a US Dollar fund. The company has branches in Beijing, Shanghai, Los Angeles, and San Francisco, and holds a US securities market license. The healthcare industry is a key focus for CEC Capital, where it has significant advantages and has been the new economy investment bank with the most healthcare industry transaction records in China for five consecutive years. Additionally, CEC Capital boasts the largest, most professional, and most comprehensively covered healthcare investment banking team in China.